DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Bioequivalence Study of Nizatidine Capsules 300 mg of Dr.Reddy's Laboratories Limited Under Non- Fasting Conditions

Information source: Dr. Reddy's Laboratories Limited
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Healthy

Intervention: Nizatidine (Drug); Axid (Drug)

Phase: Phase 1

Status: Completed

Sponsored by: Dr. Reddy's Laboratories Limited

Official(s) and/or principal investigator(s):
Charu Gautam, M.D, Principal Investigator, Affiliation: Lambda Therapeutic Research Ltd

Summary

The purpose of this study is to compare experimental evaluation of relative bioavailabilities in healthy, human subjects under non-fasting conditions.

Clinical Details

Official title: A Two-way Crossover Experimental Evaluation of Relative Bioavailabilities of Two Formulations of Nizatidine 300 mg Capsules in Healthy Human Subjects Under Non-fasting Conditions

Study design: Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Bioequivalence based on Cmax and AUC parameters

Detailed description: Open label, balanced, randomized, two-treatment, two-period, two sequence, single dose, crossover, comparative oral bioavailability study in healthy, adult, male human subjects under non-fasting conditions.

Eligibility

Minimum age: 18 Years. Maximum age: 55 Years. Gender(s): Male.

Criteria:

Inclusion Criteria:

- Healthy males between 18 and 55 years of age (inclusive) living in and around

Ahmedabad city of western part of India.

- Having a Body Mass Index (BMI) ≥ 18. 0 kg/m2 (calculated as weight in kg/ height in

m2).

- Have no significant diseases or clinically significant abnormal findings during

screening, medical history, physical examination, laboratory evaluations, ECG and X-ray recordings.

- Able to communicate effectively with study personnel. Able to give consent for

participation in the trial Exclusion Criteria:

- Known hypersensitivity or idiosyncratic reaction to nizatidine or other related

drugs.

- Any disease or condition which might compromise the haemopoietic, renal, hepatic,

endocrine, pulmonary, central nervous, cardiovascular, immunological, dermatological, gastrointestinal, or any other body system.

- Ingestion of a medication at any time in 14 days before the start of the study. In

any such case subject selection will be at the discretion of the Principal Investigator/Medical expert/co-investigator.

- Any history or presence of asthma or nasal polyp.

- A recent history of alcoholism (<2years) or of moderate (180 ml/day) alcohol use.

- Smokers, who smoke more than 10 cigarettes/day or those who cannot refrain from

smoking during study period.

- The presence of clinically significant abnormal laboratory values during screening.

- Use of any recreational drugs or history of drug addiction or testing positive in

pre-study drug scan.

- History of psychiatric disorders.

- A history of difficulty with donating blood.

- Donations of blood (1 unit or 450 ml) within 90 days prior to receiving the first

dose of study medication. Note: Incase the blood loss is ≤ 200 L, subject may be dosed after completion of 60 days of blood donation).

- A positive hepatitis screen including hepatitis B surface antigen, anti-HCV and

anti-HAV antibodies.

- A positive test result for HIV antibody and/or syphilis.

- The receipt of an investigational product or participation in a drug research study

within a period of 90 days prior to the first dose of study medication (Elimination half-life of the study drug should be taken into consideration for inclusion of the subject in the study). (Note: If subject had participated in a study in which blood loss is ≤200 mL, subject can be dosed after completion of 60 days of previous study).

- An unusual diet, for whatever reason (eg., low-sodium), for four weeks prior to

receiving the study medication and throughout the subjects, participation in the study. In any such case subject will be at the discretion of the Principal Investigator/Medical expert/Co-investigator.

Locations and Contacts

Additional Information

Starting date: July 2004
Last updated: July 13, 2010

Page last updated: August 20, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017